Analyst Price Target is $23.95
▲ +35.83% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Ortho Clinical Diagnostics in the last 3 months. The average price target is $23.95, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 35.83% upside from the last price of $17.63.
Current Consensus is
The current consensus among 7 contributing investment analysts is to buy stock in Ortho Clinical Diagnostics.
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.